GRL-0617

N/A

Report date: 2024/11/18 15:23:33
NME

Base Information

Drug NameGRL-0617
Drug Alias NameGRL-0617
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2 PLpro inhibitors
TargetsSARS-CoV-2 papain-like protease
Therapy Area/IndicationsSevere Acute Respiratory Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Illinois At Chicago
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Illinois At Chicago
Active IndicationsN/A
Inactive IndicationsSevere Acute Respiratory Syndrome

Other Information

ATC CodeN/A
Related LinksN/A